Low frequency of p53 mutations in human thyroid tumors; p53 and Ras mutation in two out of fifty-six thyroid tumours

European Journal of Endocrinology

Volumn 134, Issue 2, 1996, Pages 177-183

  Salvatore, Domenico ^a   Celetti, Angela ^a   Fabien, Nicole ^b   Paulin, Christian ^b   Martelli, Maria Luisa ^c   Battaglia, Caterina ^c   Califano, Daniela ^d   Monaco, Carmen ^d   Viglietto, Giuseppe ^d   Santoro, Massimo ^a   Fusco, Alfrede ^a,c,e  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b CENTRE HOSPITALIER LYON SUD   (France)

^c UNIVERSITY MEDITERRANEA OF REGGIO CALABRIA   (Italy)

^d NATIONAL CANCER INSTITUTE   (Italy)

^e UNIVERSITY OF CHIETI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MUTATION; ONCOGENE RAS; PRIORITY JOURNAL; THYROID TUMOR; TUMOR GROWTH;

EID: 13344280360     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1340177     Document Type: Article

References (39)

1. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K. et al. Mutations in the p53 gene occur in diverse human tumour types. Nature 1989;342:705-8
2. Lane DP. p53 and human cancers. Br Med Bull 1994;50:582-99
3. Harris CC, Hollstein M. Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 1993;329:1318-27
4. Gannon JV, Greaves R, Iggo R, Lane DP. Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific of the mutant form. EMBO J 1990;9:1595-602
5. Kupryjanczyk J. Thor AD, Beauchamp R, Merritt V, Edgerton SM, Bell DA, et al. p53 gene mutations and protein accumulation in human ovarian cancer. Proc Natl Acad Sci USA 1993;90:4961-5
6. Sidransky D, Mikkelsen T, Schwechheimer K, Rosenblum ML, Cavenee W, Vogelstein B. Clonal expansion of p53 mutant cells is associated with brain tumour progression. Nature 1992;355: 846-7
7. Donghi R, Longoni A, Pilotti S, Michieli P, Della Porta G, Pierotti MA. p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland J Clin Invest 1993;91:1753-60
8. Fagin JA, Matsuo K, Karmakar A, Chen DL, Tan SH, Koeffler HP. High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas J Clin Invest 1993;91:179-84
9. Ito T, Seyama T, Mizuno T, Tsuyama N, Hayashi T, Hayashi Y, et al. Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland. Cancer Res 1992;52:1369-71
10. Wright PA, Lemoine NR, Goretzki PE, Wyllie FS, Bond J, Hughes C, et al. Mutation of the p53 gene in a differentiated human thyroid carcinoma cell line but not in primary thyroid tumours. Oncogene 1991;6:1693-7
11. Nakamura T, Yana I, Kobayashi T, Shin E, Karakawa K, Fujita S, et al. p53 gene mutations associated with anaplastic transformation of human thyroid carcinomas. Jpn J Cancer Res 1992;83:1293-8
12. Dobashi Y, Sakamoto A, Sugimura H, Mernyei M, Mori M, Oyama T. et al. Overexpression of p53 as a possible prognostic factor in human thyroid carcinoma Am J Surg Path 1993;17:375-81
13. Zou M, Shi Y, Farid NR. p53 mutations in all stages of thyroid carcinomas. J Clin Endocr Metab 1993;77:1054-8
14. Simon D, Goretzki PE, Gorelev V, Ebling B, Reishaus E, Lyons J, et al. Significance of p53 in human thyroid tumors. World J Surg 1994;18:535-40
15. Hedinger C, Williams ED, Sobin LH. The WHO histological classification of thyroid tumors: a commentary on the second edition. Cancer 1989;63:908-11
16. Fabien N, Fusco A, Santoro M, Barbier Y, Dubois PM, Paulin C. Description of a human papillary thyroid carcinoma cell line: morphological study and expression of tumoral markers. Cancer 1994;73:2206-12
17. Hollstein M, Metcalf RA, Welsh JA, Montesano R, Harris CC. Frequent mutation of the p53 gene in human esophageal cancer. Proc Natl Acad Sci USA 1990;87:9958-61
18. Suzuki Y, Orita M, Shiraishi M, Hayashi K, Sekiya T. Detection of ras gene mutations in human lung cancers by single-strand conformation polymorphism analysis of polymerase chain reaction products. Oncogene 1990;5:1037-43
19. Santoro M, Carlomagno F, Hay ID, Herrmann MA, Grieco M, Melillo R, et al. RET oncogene activation in human thyroid neoplasms is restricted to the papillary carcinoma subtype. J Clin Invest 1992;89:1517-22
20. Bongarzone I, Pierotti MA, Monzini N, Mondellini P. Manenti G, Donghi R, et al. High frequency of activation of tyrosine kinase oncogenes in human papillary thyroid carcinoma. Oncogene 1989;4:1457-62
21. Lemoine NR, Mayall ES, Wyllie FS, Williams ED, Goyns M, Stringer B, et al. High frequency of ras oncogene activation in all stages of human thyroid tumorigenesis. Oncogene 1989;4:159-64
22. Lemoine NR, Mayall ES, Wyllie FS, Farr CJ, Hughes D, Padua RA, et al. Activated ras oncogenes in human thyroid cancers. Cancer Res 1988;48:4459-63
23. Namba H, Gutman RA, Matsuo K, Alvarez A, Fagin JA. H-ras proto-oncogene mutations in human thyroid neoplasms. J Clin Endocrinol Metab 1990;71:223-9
24. Shi Y, Zou M, Schmidt H, Juhasz F, Stenky V, Robb D, et al. High rates of ras codon 61 mutation in thyroid tumors in a iodide-deficient area. Cancer Res 1991;51:2690-3
25. Suarez HG, du Villard JA, Caillou B, Schlumberger M, Tubiana M, Parmentier C, et al. Detection of activated ras oncogenes in human thyroid carcinomas. Oncogene 1988;2:403-6
26. Suarez HG, du Villard JA. Severino M, Caillou B, Schlumberger M. Tubiana M, et al. Presence of mutations in all three ras genes in human thyroid tumors. Oncogene 1990;5:565-70
27. Wright PA, Williams ED, Lemoine NR, Wynford-Thomas D. Radiation-associated and "spontaneous" human thyroid carcinomas shown a different pattern of ras oncogene mutation. Oncogene 1991;6:471-3
28. Fusco A. Grieco M, Santoro M, Berlingieri MT, Pilotti S, Pierotti MA, et al. A new oncogene in human thyroid papillary carcinomas and their lymph-nodal metastases. Nature 1987;328:170-3
29. Grieco M, Santoro M, Berlingieri MT, Melillo RM, Donghi R, Bongarzone I, et al. PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell 1990;60:557-63
30. Ledent C, Dumont JE, Vassart G, Parmentier M. Thyroid adenocarcinomas secondary to tissue-specific expression of simian virus-40 large T antigen in transgenic mice. Endocrinology 1991;129:1391-401
31. Ledent C, Marcotte A, Dumont JE, Vassart G, Parmentier M. Differentiated carcinomas develop as a consequence of the thyroid specific expression of a thyroglobulin-human papillomavirus type E16 E7 transgene. Oncogene 1995;10:1789-97
32. Kemp CJ, Donehower LA, Bradley A, Balmain A. Reduction of p53 dosage does not increase initiation or promotion but enhances malignant progression of chemically induced skin tumors. Cell 1993;74:813-22
33. Lane DP. A death in the life of p53. Nature 1993;362:786-7
34. Wyilie FS, Haughton MF, Blaydes JP, Schlumberger M, Wynford-Thomas D. Evasion of p53-mediated growth control occurs by three alternative mechanisms in transformed thyroid epithelial cells. Oncogene 1995;10:49-59
35. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759-67
36. Kalthoff H, Schmiegel W, Roeder C, Kasche D, Schmidt A, Lauer G, et al. p53 and K-RAS alterations in pancreatic epithelial cell lesions. Oncogene 1993;8:289-98
37. Parada LF, Land H, Weinberg RA, Wolf D, Rotter V. Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation. Nature 1984;312:649-51
38. Said S. Schlumberger M, Suarez HG. Oncogenes and anti-oncogenes in human epithelial thyroid tumors. J. Endocrinol Invest 1994;17:371-9
39. Fusco A, Berlingien MT, Portelta G, Di Fiore PP, Grieco M, Vecchio G. One- and two-step transformations of rat thyroid epithelial cells by renwiral oncogenes. Mol Cell Biol 1987;7:3365-70